Enzo Biochem Revenue 2010-2022 | ENZ

Enzo Biochem revenue from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Enzo Biochem Annual Revenue
(Millions of US $)
2021 $118
2020 $76
2019 $81
2018 $101
2017 $105
2016 $103
2015 $98
2014 $96
2013 $94
2012 $103
2011 $102
2010 $97
2009 $90
Enzo Biochem Quarterly Revenue
(Millions of US $)
2022-01-31 $34
2021-10-31 $27
2021-07-31 $25
2021-04-30 $33
2021-01-31 $31
2020-10-31 $29
2020-07-31 $20
2020-04-30 $17
2020-01-31 $19
2019-10-31 $20
2019-07-31 $21
2019-04-30 $20
2019-01-31 $19
2018-10-31 $21
2018-07-31 $23
2018-04-30 $25
2018-01-31 $26
2017-10-31 $27
2017-07-31 $25
2017-04-30 $27
2017-01-31 $26
2016-10-31 $26
2016-07-31 $27
2016-04-30 $26
2016-01-31 $25
2015-10-31 $25
2015-07-31 $26
2015-04-30 $24
2015-01-31 $23
2014-10-31 $25
2014-07-31 $25
2014-04-30 $24
2014-01-31 $23
2013-10-31 $24
2013-07-31 $23
2013-04-30 $23
2013-01-31 $22
2012-10-31 $26
2012-07-31 $26
2012-04-30 $26
2012-01-31 $25
2011-10-31 $26
2011-07-31 $27
2011-04-30 $26
2011-01-31 $24
2010-10-31 $26
2010-07-31 $25
2010-04-30 $24
2010-01-31 $23
2009-10-31 $25
2009-07-31 $25
2009-04-30 $23
2009-01-31 $21
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.110B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00